Digestive Care
Digestive Care is a private US specialty pharmaceutical company that develops and manufactures PERTZYE, the only FDA-approved pancreatic enzyme replacement therapy containing bicarbonate-buffered enteric-coated microspheres, for adult and pediatric patients with exocrine pancreatic insufficiency (EPI).
- Company typePrivate
- Founded1990
- HeadquartersBethlehem, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Digestive Care does
Digestive Care, Inc. is a private specialty pharmaceutical company founded in 1990 by Ranvir Singh and headquartered in Bethlehem, Pennsylvania. The company develops, manufactures, and markets PERTZYE (pancrelipase), a prescription Pancreatic Enzyme Replacement Therapy (PERT) indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) in adult and pediatric patients. EPI is a condition in which the pancreas does not produce sufficient digestive enzymes, and is commonly associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-pancreatic surgery. PERTZYE is differentiated by its proprietary Bicarbonate-Buffered Enteric-Coated Microspheres technology, which protects the digestive enzymes from gastric acid and delivers them to the small intestine. The product line spans four lipase unit strengths (4,000, 8,000, 16,000, and 24,000) plus a G-tube formulation for patients unable to swallow capsules, supporting individualized dosing across a broad patient population.
Digestive Care operates a sales-led, prescription-based go-to-market in which healthcare providers (gastroenterologists, pulmonologists treating cystic fibrosis, and related specialists) prescribe PERTZYE and patients fill prescriptions through retail and specialty pharmacies. Distribution is US-only, with PERTZYE manufactured in the United States. The company operates between 11 and 50 employees and supports its franchise with an extensive suite of patient access and adherence programs, including a Co-Pay Card, EPI Nutrition Program, First Start Program, Infant Starter Program, My EPI Plan, Pertzye Care, and an Uninsured Patient Assistance Program.
The company remains privately held with no disclosed parent company, institutional investors, or funding rounds. Commercial activity is concentrated entirely on the PERTZYE franchise; no additional pipeline assets, partnerships, acquisitions, or geographic expansion initiatives are identified in the available data. Pricing is not publicly disclosed and is described as determined by insurance coverage, pharmacy benefit managers, and patient assistance programs.
Digestive Care firmographics
Firmographics- Name
- Digestive Care
- Legal name
- Digestive Care, Inc.
- Website
- https://digestivecare.com
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Digestive Care is a private US specialty pharmaceutical company that develops and manufactures PERTZYE, the only FDA-approved pancreatic enzyme replacement therapy containing bicarbonate-buffered enteric-coated microspheres, for adult and pediatric patients with exocrine pancreatic insufficiency (EPI).
- Ownership category
- akta.pro rank
Digestive Care industry classification
Industry- Product category
- Prescription Pharmaceuticals
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
- akta.pro secondary industry
- Pancreaticobiliary Disorders (HLAKAEAG)
Keywords
Where Digestive Care is headquartered
LocationHeadquarters
- HQ city
- Bethlehem
- HQ country
- United States
- HQ region
- North America
Markets served
Digestive Care business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Prescription Pharmaceutical Sales: Digestive Care generates revenue through the sale of prescription pancreatic enzyme replacement therapy (PERT) products. Pertzye is available in multiple dosage strengths (4000, 8000, 16000, and 24000 lipase units) and as a G-tube formulation for patients who cannot swallow capsules.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Digestive Care product offering
Product offeringCore offering
Digestive Care manufactures and markets PERTZYE (pancrelipase), a prescription pancreatic enzyme replacement therapy (PERT) for treating exocrine pancreatic insufficiency (EPI) in adult and pediatric patients. The product line is available in four capsule strengths (4000, 8000, 16000, and 24000 lipase units) plus a G-tube formulation for patients with swallowing difficulties, all built on proprietary Bicarbonate-Buffered Enteric-Coated Microsphere technology.
Product overview
Digestive Care offers a unified portfolio of prescription pancreatic enzyme replacement therapies centered on PERTZYE, the only PERT containing Bicarbonate-Buffered Enteric-Coated Microspheres. The product line consists of five dosage strengths (4000, 8000, 16000, and 24000 lipase units) plus a G-tube formulation, all designed to treat exocrine pancreatic insufficiency (EPI) in adults and children. The various lipase unit strengths allow for individualized dosing based on patient needs, while the G-tube variant addresses administration challenges for patients with swallowing difficulties. The portfolio is supported by patient assistance programs including Co-Pay Card, EPI Nutrition Program, First Start Program, Infant Starter Program, My EPI Plan, Pertzye Care, and Uninsured Patient Assistance Program.
Differentiator
Problem solved
Functional benefit
Brands
- PERTZYE: Pancreatic Enzyme Replacement Therapy (PERT) containing Bicarbonate-Buffered Enteric-Coated Microspheres, available in 4000, 8000, 16000, and 24000 lipase unit capsules
Products and services
- PERTZYE 4000 Pancreatic Enzyme Replacement Therapy (PERT) capsules containing 4000 lipase units, indicated for treatment of exocrine pancreatic insufficiency (EPI) in adult and pediatric patients.
- PERTZYE 8000
- PERTZYE 16000
- PERTZYE 24000
- PERTZYE G-tube
Companies that use Digestive Care
Customer profileSegments3 records
Ideal customer profiles3 records
Digestive Care technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Digestive Care partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights4 records
Digestive Care competitors and assessment
Company assessmentDirect peers
- Nestlé Health Science: Nestlé Health Science markets Zenpep, one of the leading US PERT products with multiple dosage strengths. Directly competes with PERTZYE in the same pancreatic enzyme replacement category for EPI patients across adult and pediatric populations.
- Chiesi Farmaceutici: Chiesi was the original developer of the PERTZYE formulation (originally branded PANCRECARB) and markets competing pancreatic enzyme products internationally. Has deep technical familiarity with the bicarbonate-buffered microsphere technology underlying Digestive Care's product.
- ANI Pharmaceuticals: ANI Pharmaceuticals markets generic and branded pancrelipase products including competing PERT formulations. Directly competes in the same EPI category with similar capsule-based delivery across multiple dosage strengths.
- AbbVie: AbbVie markets Creon, the market-leading pancreatic enzyme replacement therapy with majority share in the US PERT market. Directly competes with PERTZYE across the same gastroenterology, pulmonology, and pancreatic insufficiency prescriber base.
- Vivus: Vivus markets Pancreaze, a competing pancreatic enzyme replacement therapy capsule product. Directly competes with PERTZYE across the same EPI prescriber channels with similar capsule-based delivery and multiple dosage strengths.
Broad incumbents
- Takeda Pharmaceutical: Takeda operates a broad gastroenterology and rare disease portfolio including enzyme and GI therapies. While not a direct US PERT competitor, operates in the same gastroenterology specialty prescriber channel where Digestive Care competes for attention and formulary access.
- Bausch Health (Salix Pharmaceuticals): Salix Pharmaceuticals is Bausch Health's gastroenterology specialty division with a broad GI product portfolio including pancreatic enzymes (historically Viokace). Operates in the same gastroenterology prescriber channel as Digestive Care with overlapping physician relationships.
Emerging players
- Alcresta Therapeutics: Alcresta specializes in pancreatic enzyme products for pediatric and tube-fed patients including those with cystic fibrosis. Adjacent PERT competitor focused on specialized delivery formats that overlap with PERTZYE's G-tube and pediatric positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Digestive Care social profiles
Digital presenceDigestive Care financial estimates
Financial estimateRevenue estimate
Valuation estimate
Digestive Care leadership team
Management profileNumber of profiles
Profiles1 record
Digestive Care funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Digestive Care M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Digestive Care
What does Digestive Care do?
Digestive Care manufactures and markets PERTZYE (pancrelipase), a prescription pancreatic enzyme replacement therapy (PERT) for treating exocrine pancreatic insufficiency (EPI) in adult and pediatric patients. The product line is available in four capsule strengths (4000, 8000, 16000, and 24000 lipase units) plus a G-tube formulation for patients with swallowing difficulties, all built on proprietary Bicarbonate-Buffered Enteric-Coated Microsphere technology.
Is Digestive Care a public or private company?
Digestive Care is a private company. It is classified as unknown and is currently operating.
When was Digestive Care founded?
Digestive Care was founded in 1990. It employs 11 to 50 people.
Where is Digestive Care based?
Digestive Care is headquartered in Bethlehem, United States, in the North America region.
How does Digestive Care make money?
One revenue line is on record: prescription Pharmaceutical Sales.
Who are Digestive Care's main competitors?
Direct peers on record are Nestlé Health Science, Chiesi Farmaceutici, ANI Pharmaceuticals, AbbVie and Vivus. Broad incumbents are Takeda Pharmaceutical and Bausch Health (Salix Pharmaceuticals). Alcresta Therapeutics is listed as an emerging player.
Does Digestive Care have an API?
No public API is recorded for Digestive Care.
What industry is Digestive Care in?
Digestive Care's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAKAEAG, Pancreaticobiliary Disorders.